Popular Weight-Loss Drugs Found To Cut Heart Attack and Stroke Risk

A large review of 11 trials and more than 90,000 patients found GLP-1 receptor agonists cut major cardiovascular events by about 13% versus placebo.

The benefit held over nearly three years and was seen in patients both with and without diabetes.

The drugs were linked to lower risks of heart attack, stroke, and cardiovascular death, suggesting protection beyond weight and glucose control.

The findings could support broader use of semaglutide, liraglutide, and dulaglutide in people at elevated heart risk.